What question did this study set out to answer?

To evaluate the durability of antibody responses up to six months after two COVID-19 vaccine doses and initial humoral responses following a third dose in people living with HIV on suppressive antiretroviral therapy compared to controls.

June 7, 2022The Journal of Infectious DiseasesOpen Access

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

View Full Paper

Ask AI

Bookmark

Authors

HLHope R. LapointeAIDS Vancouver FMFrancis MwimanziSimon Fraser University PCPeter K. CheungChinese University of Hong Kong

Discussion

Member takes

Implication

Cohort study demonstrates robust antibody durability and booster responses in people with HIV on suppressive therapy, highlighting the protective benefit of third COVID-19 vaccine doses.

Key Points

To evaluate the durability of antibody responses up to six months after two COVID-19 vaccine doses and initial humoral responses following a third dose in people living with HIV on suppressive antiretroviral therapy compared to controls.
Assessed 99 people living with HIV receiving suppressive antiretroviral therapy and 152 controls up to 6 months after a 2-dose vaccination series and 1 month after a third dose.
Measured binding antibodies to the SARS-CoV-2 spike receptor-binding domain, ACE2 displacement, and viral neutralization against wild-type and Omicron variants.
Found no evidence of lower antibody concentrations, faster decay rates, or poorer neutralization after two doses in people living with HIV compared to controls, with low nadir CD4+ T-cell counts having no detrimental effect.
Third-dose humoral responses substantially exceeded two-dose levels and were comparable to or higher in people living with HIV than controls, with an mRNA-1273 booster showing the strongest positive association despite broadly reduced neutralization against Omicron.

Cite This Study

Lapointe et al. (2022) studied this question.

synapsesocial.com/papers/6a764b848e31ea4274087dc7 https://doi.org/10.1093/infdis/jiac229

View Full Paper

Ask AI

Bookmark

Implication

Cohort study demonstrates robust antibody durability and booster responses in people with HIV on suppressive therapy, highlighting the protective benefit of third COVID-19 vaccine doses.

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

Discussion

Member takes

Implication

Key Points

Cite This Study

People With Human Immunodeficiency Virus Receiving Suppressive Antiretroviral Therapy Show Typical Antibody Durability After Dual Coronavirus Disease 2019 Vaccination and Strong Third Dose Responses

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider